Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterisation and comparison of Mycoplasma bovis strain types from Irish and Scottish bovine isolates in a global context.
McAloon CI, Farrell D, Smith J, Gordon SV, Sheehan M, Kennedy A, Geraghty T, Mason C, Leggett B, Leonard FC, Sweeney T, McGrath G, O'Shaughnessy J, O'Rourke J, Ridley A, Deeney A, More SJ. McAloon CI, et al. Among authors: o shaughnessy j. Vet Microbiol. 2025 Jan;300:110339. doi: 10.1016/j.vetmic.2024.110339. Epub 2024 Dec 6. Vet Microbiol. 2025. PMID: 39671757 Free article.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.
Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, García Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez Rodriguez JL, Ruíz Borrego M, Nakamura R, Pradhan KR, Cramer von Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard FC; EMBER-3 Study Group. Jhaveri KL, et al. Among authors: o shaughnessy j. N Engl J Med. 2024 Dec 11. doi: 10.1056/NEJMoa2410858. Online ahead of print. N Engl J Med. 2024. PMID: 39660834
Advancing alternative methods to reduce animal testing.
Nelson CP, Brown P, Fitzpatrick S, Ford KA, Howard PC, MacGill T, Margerrison EEC, O'Shaughnessy J, Patterson TA, Raghuwanshi R, Rouse R, Stromgren S, Sung KE, Valerio LG Jr, Ward JL, Bumpus NN. Nelson CP, et al. Among authors: o shaughnessy j. Science. 2024 Nov 15;386(6723):724-726. doi: 10.1126/science.adg6228. Epub 2024 Nov 14. Science. 2024. PMID: 39541448
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, Colleoni M, Kaczmarek E, Punie K, Song X, Armstrong A, Bianchi G, Stradella A, Ladoire S, Lim JSJ, Quenel-Tueux N, Tan TJ, Escrivá-de-Romaní S, O'Shaughnessy J; TULIP Trial Investigators. Turner N, et al. Among authors: o shaughnessy j. J Clin Oncol. 2024 Oct 23:JCO2400529. doi: 10.1200/JCO.24.00529. Online ahead of print. J Clin Oncol. 2024. PMID: 39442070
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: o shaughnessy j. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282906 Clinical Trial.
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Lévy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Bardia A, et al. Among authors: o shaughnessy ja. N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2407086. Online ahead of print. N Engl J Med. 2024. PMID: 39282896
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
Bardia A, Cortés J, Bidard FC, Neven P, Garcia-Sáenz J, Aftimos P, O'Shaughnessy J, Lu J, Tonini G, Scartoni S, Paoli A, Binaschi M, Wasserman T, Kaklamani V. Bardia A, et al. Among authors: o shaughnessy j. Clin Cancer Res. 2024 Oct 1;30(19):4299-4309. doi: 10.1158/1078-0432.CCR-24-1073. Clin Cancer Res. 2024. PMID: 39087959 Free PMC article. Clinical Trial.
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
Dent RA, Kim SB, Oliveira M, Barrios C, O'Shaughnessy J, Isakoff SJ, Saji S, Freitas-Junior R, Philco M, Bondarenko I, Lian Q, Bradley D, Hinton H, Wongchenko MJ, Reilly SJ, Turner N. Dent RA, et al. Among authors: o shaughnessy j. Clin Cancer Res. 2024 Oct 1;30(19):4329-4338. doi: 10.1158/1078-0432.CCR-24-0465. Clin Cancer Res. 2024. PMID: 39058425 Free PMC article. Clinical Trial.
441 results